top of page

NEXT  GENERATION  DRUGS  TO  TREAT
AUTOIMMUNE,  CHRONIC   INFLAMMATORY   DISEASE
AND  CANCER

ABOUT SFA THERAPEUTICS

Our journey began with a deep fascination for the intricate world of the human gut bacterial ecosystem and its profound impact on overall well-being.  Our founders, a team of passionate researchers and healthcare professionals, were intrigued by the pivotal role this complex microbiota plays in maintaining human health.  The various bacteria produce a complex, yet synergistic, set of metabolites in our intestines that exhibit profound, wide-ranging effects on metabolism and immune function.

​​

​​

​​

​As we delved deeper into the science, we uncovered the potential of these biosynthetic molecules, that mimic naturally occurring substances, in addressing a variety of health challenges, from autoimmune disease to metabolic disorders. We were particularly captivated by how these simple organic compounds could influence complex cellular processes and serve as a communication bridge between our gut microbiome and immune system.

​

​​

​​​​​

We discovered ways of increasing the selectivity and specifictiy of our biosynthetics after elucidating pathways and targets.  We have developed a platform technology that allows us to target specific diseases and create disease-specific drugs.  â€‹â€‹â€‹â€‹Our technology platform represents a convergence of microbial science, pharmaceutical innovation, and precision medicine, offering new hope for patients across multiple therapeutic areas.  

​

​Join us on this exciting journey as we work towards a healthier future, one molecule at a time.

Picture8.png
Picture8.png

INNOVATIVE  DRUGS 

PREDICTABLE OUTCOMES

Innovative Oral   Formulations Allow for Consistent Clinical Outcomes

PATHWAY TARGETED

Small Molecules that Interact Selectively with Disease-specific Targets and Maintain Immune Homeostasis  

SUPERIOR 
SAFETY

Small Molecules that Mimic Endogenous Substances found in the Human Body
 

HIGHLY EFFICACIOUS

Boosts Anti-inlammatory IL-10 Expression and Downregulates Pro-inflammatory Cytokines

LOW COST

Seamless Manufacturing Process 

 POWERFUL  and  NOVEL  PLATFORM

102158395_eps_normal_none [Converted].png

1

2

3

4

Antibody Icon
Picture46_edited.png
Picture45.png

TARGETED BIOSYNTHESIS

PLATFORM

5

Picture48.png

AUTOIMMUNE DISEASES

PSORIASIS, RHEUMATOID ARTHRITIS,

UVEITIS AND BULLOUS PEMPHIGOID

CANCERS

HEPATOCELLULAR CARCINOMA, PANCREATIC CANCER AND MYELOID LEUKEMIAS

INFECTIOUS DISEASES

POST-VIRAL INFLAMMATORY COMPLICATIONS​

LIVER DISEASES

FIBROSIS AND MASH/NASH â€‹

ANTI-INFLAMMATORY ADJUVANTS

CAR-T THERAPIES

OUR PARTNERS

SFA THERAPEUTICS
IS  A

VENTURE  CAPITAL  BACKED  CLINICAL-STAGE  BIOTECHNOLOGY COMPANY

Asymmetry Ventures Logo.png
North South Ventures Logo.png
Acequia Capital Logo.png
Savantus Ventures Logo.png
Ben Franklin Logo.webp
Boost VC Logo.png
INP Logo.png
ReInforced Ventures Logo.webp
Y Combinator.webp

SFA  THERAPEUTICS  IN  THE  NEWS

195420267_xl_normal_none.jpg

JENKINTOWN, Pa., May 17, 2024 BUSINESS WIRE -- Article by SFA Therapeutics Founders Featured in Drug Target Review

READ MORE >>

JENKINTOWN, Pa., May 2, 2024 PRNewswire -- SFA Therapeutics Strengthens Management Team with Appointment of Chief Medical Officer

READ MORE >>

JENKINTOWN, Pa., February 29, 2024 BUSINESS WIRE -- Ben Franklin Healthcare Investments: 1.3 Million in Four Companies

READ MORE >>

JENKINTOWN, Pa., December 7, 2023 BUSINESS WIRE -- SFA Therapeutics Announces Updated Psoriasis Data for SFA-002, Bridge Financing, and Foundational Patent

READ MORE >>

JENKINTOWN, Pa., August 14, 2023 BUSINESS WIRE -- SFA Therapeutics announces results for SFA-002 from Phase 1b Cohort 1 clinical trial for treatment of mild-to-moderate psoriasis

READ MORE >>

JENKINTOWN, Pa., August 14, 2023 BUSINESS WIRE -- SFA Therapeutics Founders Publish an Article Titled “Short‑chain fatty acids in cancer pathogenesis”

READ MORE >>

bottom of page